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COVID-19 has currently become a major global 
health problem. Due to novelty and high morbidity 
and mortality, there are some important medical 
challenges to achieve proper management and 
treatment of the disease. Different pharmaceutical 
categories have been candidate for viral or 
cytokine phase control, and in this regard many 
clinical trials are underway to obtain evidences and 
acceptable results (1). One of these compounds is 
magnesium (Mg) sulfate which may have potential 
therapeutic effect on the cytokine phase of COVID-
19. Mg compounds have long been used in practice 
under various indications and purposes as 
supplemental compounds, electrolyte regulation 
and also prevention of drugs side effects. In 
addition, the effectiveness of Mg sulfate in 
controlling asthma attacks, gynecological cases and 
pre-natalogical problems has also been proven. 
Herein we briefly reviewed immunomodulatory 
and respiratory effects of Mg and its potential 
benefits in COVID-19 treatment. Mg sulfate can be 
used both systemically and by inhalation, but 
nebulizer route has potential effect on rapid onset 
of action on respiratory system and reduced 
incidence of systemic side effects (2). To the best of 
our knowledge, in COVID-19 patients, as other viral 
infections, airway hyper-reactiveness can be 
overrepresented (3). In this regard ventilation 
improvement and reducing of airway resistance 
should be considered. Some bronchodilators, such 
as β2-agonists and anti-muscarinic agents used to 
relieve these symptoms. Another option has 
provided for hospitalized patients, is nebulized Mg 
sulfate. It has been suggested in the literature that 
Mg sulfate can cause bronchodilation in asthmatic 
patients by various mechanisms, including by 
inhibition of calcium influx into the cytosol, 
prevention of acetylcholine secretion, inhibition of 
histamine release; and finally, by β2-receptor 
affinity enhancement, increases bronchodilator 
effect of β2-agonists (4). On the other hand, 
according to some researches, low Mg level is 
associated with increased inflammatory response.  
in vitro studies showed that short-term exposure 
to Mg sulfate without affecting on viability and 
function of phagocytes, diminished cytokine gene 
and protein expression, and consequently could 
reduce production of TNF-α and IL-6 from neonatal 
monocytes (5). Moreover, Mg sulfate can reduce 
the level of interleukin 1β, that is a potent pro-
inflammatory cytokine (6). Another study of the 
anti-inflammatory effect of Mg compounds showed 
that neutralized Mg ions can convert THP-1-
derived macrophages to the M2 phenotype (anti-
inflammatory macrophages), thereby reduce the 
production of inflammatory cytokines and enhance 
the secretion of anti-inflammatory cytokines. As 
well as, according to in vitro and in vivo studies, Mg 
sulfate significantly reduces baseline level along 
with LPS-stimulated cytokine production (5, 6). 
Altogether, given that the cytokine phase of COVID-
19 plays a very significant role in patient morbidity 
and mortality, therefore proper management and 
control of this stage of the disease is important on 
rescuing patients. It seems that, administration of 
Mg compounds as an adjuvant treatment may 
improve this condition of disease. Our preliminary 
experiences indicated the potential positive effects 
of Mg sulfate on the improvement process in covid-
19. However, in order to achieve more accurate and 
reliable results, adequate randomized clinical trials 
are needed. It should be considered that 
intravenous administration of this drug can be 
performed only in the intensive care unit (ICU) and 
or under close observation, but the Inhaler form 
does not require close monitoring. Moreover, oral 
Mg supplementation in outpatients may also 
reduce the inflammatory response in COVID-19.
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